Two Ongoing Clinical Trials of IPI-145 for Hematologic Malignancies

June 5, 2014
Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.

DUO

- DUO is a randomized, phase III trial comparing IPI-145 to ofatumumab for patients with relapsed or refractory CLL or SLL.

- Ofatumumab is a CD20-directed cytolytic monoclonal antibody approved for the treatment of CLL.

- Patients in this trial are randomized 1:1 and are able to cross over.

DYNAMO

- DYNAMO is a single-arm, phase II trial of patients with non-Hodgkin lymphoma that are no longer responding to rituximab or chemotherapy.

- There is currently no established therapy for this group of patients.

<<<

View more from the 2014 ASCO Annual Meeting